It's time to deliver differently.
Accessed: 13.11.2019
Technical Report
AIDS Medicines and diagnostics service
September 2016
Supplement Article
J Acquir Immune Defic Syndr Volume 75, Supplement 2, June 1, 2017 www.jaids.com
Journal of Pulmonary & Respiratory Medicine 6: 326. doi:10.4172/2161-105X.1000326
Legislative and Policy analysis and recommendations for reform
Research Article
PLOS ONE | https://doi.org/10.1371/journal.pone.0189770 January 2, 2018
Recommendations, resources and references
A publication of the Southern African HIV Clinicians Society
Avec l’essor des traitements antirétroviraux (TAR) à base de dolutégravir (DTG) pour soigner les personnes vivant avec
le VIH dans le monde, il est important d’estimer la vitesse à laquelle la résistance acquise au DTG apparaît dans les
...populations sous TAR. Bien que la résistance au DTG ne soit pas apparue dans les populations naïves aux TAR incapables
de supprimer la charge virale dans les essais cliniques, certains éléments portent à croire que la résistance au
DTG peut émerger chez les personnes suivant des schémas thérapeutiques incluant le DTG. L’OMS recommande aux
pays qui étendent les TAR incluant le DTG d’accompagner ce déploiement d’une surveillance en routine de la pharmacorésistance
more
The objectives of these guidelines are to provide recommendations outlining a public health approach to managing people presenting with advanced HIV disease, and to provide guidance on the timing of initiation of antiretroviral therapy (ART) for all... people living with HIV.
WHO recommends that a package of screening, prophylaxis, rapid ART initiation and intensified adherence interventions be offered to everyone living with HIV presenting with advanced disease.
WHO strongly recommends that rapid ART initiation should be offered to people living with HIV following confirmed diagnosis and clinical assessment. Rapid initiation of ART is defined as within seven days of HIV diagnosis. WHO further strongly recommends ART initiation on the same day as HIV diagnosis based on the person’s willingness and readiness to start ART immediately, unless there are clinical reasons to delay treatment.
more
BMJ,Dodd PJ, et al. Thorax 2017;72:559–575. doi:10.1136/thoraxjnl-2016-209421
These guidelines provide new and updated recommendations on the use of point-of-care testing in children under 18 months of age and point-of-care tests to monitor treatment in people living with HIV; the treatment monitoring algorithm; and timing of antire...troviral therapy (ART) among people living with HIV who are being treated for tuberculosis.
New recommendations launched today outline key new actions that countries can take to improve the delivery of HIV testing, treatment and care services by providing greater options for differentiated approaches such as, supporting HIV treatment start in the community, ensuring that children are diagnosed and treated early, and that viral load treatment monitoring is more accessible, focused and triggers clinical action
more